Pharmacy leaders have issued a stark warning about the risks posed by the growing online availability of weight-loss injections. The National Pharmacy Association (NPA) has highlighted cases of patients with previous eating disorders or low body weight being inappropriately prescribed drugs such as Wegovy and Mounjaro, underscoring the urgent need for tighter controls.
In a letter to the General Pharmaceutical Council (GPhC), the NPA called for stricter regulations to address the risks, including mandatory in-person consultations lasting at least 20 minutes. They criticised the reliance on online questionnaires, which they argue are inadequate for assessing the medical history and suitability of patients.
NPA chairman Nick Kaye emphasised the need to prioritise patient safety over commercial incentives. "Clinical decisions regarding weight-loss injections should never be influenced by financial targets or incentives," he said.
The warning comes as demand for weight-loss injections is set to surge, with the government planning to expand their availability on the NHS.
"Obesity is one of the biggest challenges facing our country, and pharmacies are committed to supporting patients in managing their weight," Mr Kaye told the PA news agency. "However, the current regulations leave the door open for misuse, allowing some patients to access these medications without proper consultation or a review of their medical history."
The NPA insists that weight-loss injections should only be prescribed as part of a carefully managed treatment programme for patients who genuinely need them. They argue that a more robust consultation process is essential to minimise risks and ensure that these medications are used responsibly and effectively.
This call for action highlights the tension between addressing the UK's obesity crisis and ensuring the safe and appropriate use of powerful medications. As the rollout of weight-loss jabs expands, pharmacies are urging regulators to act swiftly to prevent further harm.